Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma.

Journal: Computer methods and programs in biomedicine
Published Date:

Abstract

BACKGROUND AND OBJECTIVE: The O-methylguanine-DNA-methyltransferase (MGMT) promoter methylation has been shown to be associated with improved outcomes in patients with glioblastoma (GBM) and may be a predictive marker of sensitivity to chemotherapy. However, determination of the MGMT promoter methylation status requires tissue obtained via surgical resection or biopsy. The aim of this study was to assess the ability of quantitative and qualitative imaging variables in predicting MGMT methylation status noninvasively.

Authors

  • Vasileios G Kanas
    Department of Electrical and Computer Engineering, University of Patras, Patras, Greece; Department of Computer Engineering and Informatics, University of Patras, Patras, Greece.
  • Evangelia I Zacharaki
    Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, AP-HP, Université Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.) and Pulmonary Department (R.C.), Hôpital Arnaud de Villeneuve, CHU de Montpellier, Université de Montpellier, Montpellier, France; ERN-Lung CF Network, France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Santé, Paris, France (N.P.).
  • Ginu A Thomas
    Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pascal O Zinn
    Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
  • Vasileios Megalooikonomou
    Department of Computer Engineering and Informatics, University of Patras, Patras, Greece.
  • Rivka R Colen
    Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.